Adagio Medical Holdings, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $14.4M
- Price
- $0.6491
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.37%
- Volume
- 351.1K
About
Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.
Quick stats
Shares outstanding22.2M
Computed float19.0M
Float / shares85.5%
Cash runway (months)5.7
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002006986
Websitehttps://adagiomedical.com
AI Summary
AI-generated1/13
majormixedearnings
Adagio Medical Reports Second Quarter 2026 Results
Adagio reported a Q2 net loss of $6.7 million, or $(0.30) per share, with revenue remaining nil due to a pause in commercial activity in Europe.
The company achieved key clinical milestones, submitting a PMA application to the FDA for its vCLAS Ventricular Ablation System and presenting pivotal data from the 209-patient FULCRUM-VT trial showing 84% freedom from ICD shock.
Despite treating the first patient with its next-gen vCLAS Ultra catheter, the cash balance fell to $7.7 million from $17.1 million at year-end, indicating a tightening financial runway.
Red flags
- Cash balance declined to $7.7 million from $17.1 million at year-end 2025, indicating limited runway and high burn rate.
- Net loss widened year-over-year to $6.7 million from $3.9 million.
- Revenue was nil due to paused commercial activity in Europe.